Get Free Consultation

Email Us:  support@cspanresearchsol.com

Head Office +91 8729085230

Guru Angad Nagar,
New Delhi 110092

09.00 to 18.00 Monday to Saturday

Industry Detail
  • Home
  • Industry Detail

Market Overview:

Global Proteomics Market is expected to offer an absolute $ opportunity of USD 117,350.9 million over the forecast period 2022-2035.

Proteomics Market size is estimated to reach USD 144,865.5 Million by the end of 2035, growing at a CAGR of 13.8% during the forecast period, i.e., 2022-2035. Proteomics is used to investigate: when and where proteins are expressed. rates of protein production, degradation, and steady-state abundance. how proteins are modified (for example, post-translational modifications (PTMs) such as phosphorylation) the movement of proteins between subcellular compartments.

Global Market Size, Forecast, and Trends the Over 2022 - 2035:

Base Year2022
Forecast Year2024-2035
CAGR13.80%
Base Year Market Size (2022)USD XX Million
Forecast Year Market Size (2035)USD 1,44,865.5 Million

Due to the rise in chronic diseases such as cancer, diabetes, CVDs, respiratory disorders, CKD, and others globally the use of proteomics is imperative in the current research. Study of Almost one in six deaths in 2020, or over 10 million deaths, were related to cancer, according to the WHO. Changing disease patterns are pushing the boundaries of limitations for more targeted response. As the demand for precision medicine is on the rise, research is inclining to investigate the nature of protein action and its responses at the wider scale. Proteomics offer more opportunities than genomics research.

Application Assessment Analysis: 

Several categories of biomarkers are listed across disease, such as SAA1, SAA2, TFPI, MDK, DPN, MMP2 among others in lung cancer, Prostate cancer (TMPRSS2-ERG, CD 44 antigen), Parkinson (PRNP, HSPG2, MEGF8, NCAMI SPPI, LPR1, similarly for other disease. They are regards as promising protein biomarkers for the targeted proteomics assay. 

Current Trends in Proteomic Applications: 

Wide variety of application trends have been investigated in the report. Few of them provided below.

  • PRM, SRM and DIA cellular signaling network
  • Protein microarray chips
  • Functional microarray
  • Reverse-phase protein microarray
  • Proteomic of the disease
  • Clinical proteomic
  • Analytical protein microarray
  • Gel based proteomics

Technological Limitations Associated with Proteomic Analysis Explored in the Report:

  • Membrane Proteome
  • Serum Proteomics and Biomarker Discovery
  • Advantages and Technical Limitations of Two-Dimensional Electrophoresis
  • DIGE
  • iTRAQ
  • Among others

Market Enablers

  • Rising Collaborations and Rapid Technological Advancements in Product Development 
  • Growing Product Performance and Innovations for Improved Quantification

Market Challenges 

  • Cost of Instruments for Proteomics- 
  • Difficulties with Samples and Sample Preparation Methods
  • Shortage of Skilled Professionals

Proteomics Segmentation Analysis:

Application (Clinical Diagnostics, Drug Discovery): 

The drug discovery segment touched USD 11,453.7 million in base year (2022) and is expected to have a value of USD 66,534.7 million by 2035, rising at a substantial CAGR of 14.18% over the projected time period. This segment is also growing at the highest rate due to rising research related activities. Technological advancements are making substantial progress across various areas in the market.

Regional Market Overview:

Currently, North America market is expected to offer an $ opportunities of USD XX million over the forecast period. Most lucrative market is United States, which is offering numerous market opportunities for market players. Asia Pacific is expected to grow at a growth rate of 15.64% during projected period.

Market Segmentation:

Our in-depth analysis of the global Proteomics Market includes the following segments:

Global Proteomics Market
Base Year:2022Forecast Period:2024-2035
Historical Data:2022Market Size in 2022:USD XX Million
Forecast Period 2024-35 CAGR:13.80%Market Size in 2035:USD 1,44,865.5 Million
Segments Covered:By Component

 

  • Instrument
  • Reagents
  • Software & Services
By Application
  • Clinical Discovery
  • Drug Discovery
  • Others
By End User
  • Hospitals
  • Clinical Laboratories
  • Bio-pharmaceutical Companies
  • Academic & Research Laboratories
  • Others 
By Region
  • North America (U.S., Canada)
  • Europe (United Kingdom, Germany, France, Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea, Rest of APAC)
  • Middle East & Africa (Saudi Arabia, Israel, UAE, South Africa, Rest of MEA)
  • South America (Brazil, Mexico, Argentina, Rest of South America)
Key Market Drivers:
  • Rising Collaborations and Rapid Technological Advancements in Product Development 
  • Growing Product Performance and Innovations for Improved Quantification Accuracy
Key Market Restraints:
  • Difficulties with Samples and Sample Preparation Methods
Key Trends:
  • Technological advancements
Companies Covered in the Report:
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Luminex Corporation
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Waters Corporation
  • Biognosys Technologies Pvt. Ltd.
  • HORIBA, Ltd.
  • Perseus Proteomics Inc.
  • FIMECS, Inc.
  • Olink Holding AB
  • Other Major Players

Recent Developments in the Market:

  • Thermo Fisher Scientific Inc. acquired PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry, and included it within the Laboratory Products and Biopharma Services segment. The addition of PPD’s clinical research services enhanced its offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process.
  • Bruker expanded its proteomics strategy with the addition of key capabilities from three companies named PreOmics, Prolab Instruments, and PepSi, which complement Bruker proteomics solutions. Moreover, in January 2022, it announced the closure of the majority acquisition of advanced proteomics CRO Biognosys.

Place An Order

Related Reports